Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 7/15/26 | Roche (RO) | Gazyva for Membranous Nephropathy | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/15/26 | Roche (RO) | Gazyva for Nephrotic Syndrome | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/11/26 | Novo Nordisk (NVO) | Alhemo for Hemophilia A and B - General Clotting Products | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/10/26 | GSK (GSK) | risvutatug rezetecan for Small Cell Lung Cancer (SCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
| 7/9/26 | Kailera (KLRA) | ribupatide for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/08/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/17/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |